Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TEVA
TEVA logo

TEVA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
35.960
Open
35.770
VWAP
35.89
Vol
161.24K
Mkt Cap
41.60B
Low
35.770
Amount
5.79M
EV/EBITDA(TTM)
10.68
Total Shares
1.16B
EV
55.26B
EV/OCF(TTM)
32.24
P/S(TTM)
2.45
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Show More

Events Timeline

(ET)
2026-04-29
09:10:00
U.S. Futures Slightly Lower, Focus on Fed Decision
select
2026-04-29
08:40:00
Expects Non-GAAP Margin to Gradually Increase, Plans Share Repurchase
select
2026-04-29
08:30:00
Company Expects Margin Expansion to 30% OPM by '27
select

News

seekingalpha
8.0
05-08seekingalpha
HHS Considers Restrictions on Antidepressant Use Amid Mental Health Crisis
  • Mental Health Crisis Response: HHS announced the launch of the 'MAHA Action Plan' at the Mental Health and Overmedicalization Summit, aimed at addressing the overprescription of psychiatric medications, particularly among children, highlighting a commitment to improving mental health.
  • Current Medication Usage: A 2026 study revealed that 16.6% of Americans are taking antidepressants, indicating the prevalence of these medications and their significant impact on public health.
  • Shift in Policy Direction: HHS Secretary RFK Jr. emphasized a future shift in treatment standards towards prevention, transparency, and a more holistic approach, supporting patient autonomy and informed consent, reflecting a reevaluation of mental health treatment methods.
  • SSRIs Ban Discussion: Despite discussions about potentially banning selective serotonin reuptake inhibitors (SSRIs), an HHS spokesperson clarified that no such discussions have taken place, indicating uncertainty in the policy-making process.
Newsfilter
1.0
05-04Newsfilter
Teva Pharmaceuticals to Present at BofA Healthcare Conference
  • Conference Schedule: Eric Hughes, Teva's EVP of Global R&D and Chief Medical Officer, will present at the BofA Securities Healthcare Conference on May 12, 2026, at 9:20 AM Pacific Time (12:20 PM Eastern Time), highlighting the company's latest advancements in biopharmaceuticals.
  • Live Webcast Access: The presentation will be accessible via Teva's Investor Relations website, with archived versions available within 24 hours post-presentation and accessible for up to 30 days, ensuring timely access to critical information for investors.
  • Company Transformation Strategy: Teva is transforming into a leading innovative biopharmaceutical company, committed to addressing patient needs through its world-class generics business, showcasing its innovation in neuroscience and immunology to further solidify its market position.
  • Caution on Forward-Looking Statements: Teva cautions investors that the conference content may include forward-looking statements regarding financial guidance and future performance expectations, which are subject to various risks and uncertainties that could cause actual results to differ significantly from those anticipated.
moomoo
6.0
05-01moomoo
TEVA PHARMACEUTICALS: UBS Increases Price Target from $36 to $42
  • Price Increase Announcement: Teva Pharmaceuticals has raised its target price from $36 to $42.
  • Market Impact: This adjustment reflects a positive outlook for the company's performance in the pharmaceutical market.
NASDAQ.COM
8.5
04-30NASDAQ.COM
Latest Developments in the Biotech Sector
  • Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
  • Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
  • Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
  • Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
Newsfilter
8.5
04-30Newsfilter
Teva Exceeds All Sustainability Bond Targets
  • Sustainability Achievements: Teva's 2025 Healthy Future Report reveals that it has surpassed all sustainability bond targets linked to approximately $7.5 billion in debt issuance, demonstrating significant progress in climate action and health equity.
  • Greenhouse Gas Reduction: Teva has achieved a 39% reduction in Scope 1 and 2 greenhouse gas emissions since 2019, and a 32% reduction in Scope 3 emissions since 2020, both exceeding the 25% reduction targets, indicating proactive efforts in minimizing environmental impact.
  • Expanded Patient Access: Through its global access to medicines programs, Teva has reached nearly 8 million people via product donations and approximately 399,000 through health system strengthening initiatives, showcasing the company's commitment to improving health outcomes worldwide.
  • Compliance Training Coverage: More than 99% of Teva's active employees have completed compliance and ethics training, and 66% of significant suppliers have undergone sustainability performance evaluations, reflecting the company's strong standards for responsible and ethical practices across its operations.
Yahoo Finance
8.5
04-30Yahoo Finance
Teva Acquires Emalex to Boost Growth Strategy
  • Acquisition Overview: Teva Pharmaceuticals will acquire neuroscience specialist Emalex for $700 million upfront and up to $200 million in potential milestones, effectively supporting Teva's 'pivot to growth' strategy aimed at enhancing its market position in neuroscience.
  • New Drug Development Progress: Emalex's ecopipam, a first-in-class therapy for pediatric Tourette's syndrome, has secured a Phase III win and is expected to file for FDA approval in the second half of 2026, potentially becoming the first new drug in over a decade to enter the market and fill a significant gap.
  • Market Competitive Advantage: Unlike existing dopamine D2 receptor-targeting medications, ecopipam targets the D1 receptor, which may offer improved efficacy and safety, addressing unmet needs in pediatric patients, and is projected to boost Teva's margin profile with peak U.S. sales reaching $1 billion by 2035.
  • Strategic Investment Focus: While acquiring Emalex, Teva emphasizes its ongoing strategy to focus on late-stage, de-risked, and differentiated assets, particularly in neurology and inflammation, to support the continued growth of its innovative medicines portfolio without the pressure of an impending patent cliff.
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
Wall Street analysts forecast TEVA stock price to rise
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
29.00
Averages
35.71
High
40.00
Current: 0.000
sliders
Low
29.00
Averages
35.71
High
40.00
Barclays
NULL
to
Overweight
maintain
$38 -> $40
AI Analysis
2026-05-06
New
Reason
Barclays
Price Target
$38 -> $40
AI Analysis
2026-05-06
New
maintain
NULL
to
Overweight
Reason
Barclays raised the firm's price target on Teva to $40 from $38 and keeps an Overweight rating on the shares.
Goldman Sachs
Buy
maintain
$45 -> $50
2026-04-30
Reason
Goldman Sachs
Price Target
$45 -> $50
2026-04-30
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Teva to $50 from $45 and keeps a Buy rating on the shares. Teva delivered encouraging results, with strong outperformance in its branded business and additional support from a deal that appears consistent with its stated strategy of pursuing clinically de-risked, mid-sized opportunities with commercial synergies, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TEVA
Unlock Now

Valuation Metrics

The current forward P/E ratio for Teva Pharmaceutical Industries Limited.. (TEVA.N) is 13.33, compared to its 5-year average forward P/E of 5.10. For a more detailed relative valuation and DCF analysis to assess Teva Pharmaceutical Industries Limited..'s fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
5.10
Current PE
13.33
Overvalued PE
7.32
Undervalued PE
2.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
7.43
Current EV/EBITDA
12.77
Overvalued EV/EBITDA
9.58
Undervalued EV/EBITDA
5.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.98
Current PS
2.42
Overvalued PS
1.43
Undervalued PS
0.52

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

si quiero con acciones de estados unidos
Intellectia · 30 candidates
Market Cap: >= 10.00BRegion: USPrice: $10.00 - $60.00Analyst Consensus: Strong BuyPe Ttm: 5 - 30List Exchange: XNYS, XNAS
Ticker
Name
Market Cap$
top bottom
BAC logo
BAC
Bank of America Corp
384.66B
SLB logo
SLB
SLB NV
78.36B
NU logo
NU
Nu Holdings Ltd.
73.40B
B logo
B
Barrick Mining Corp
71.97B
MFC logo
MFC
Manulife Financial Corp
64.64B
BKR logo
BKR
Baker Hughes Co
58.68B
top 10 crypto gainers today
Intellectia · 512 candidates
Price Change Pct 24h: >= $0.00
Ticker
Name
Market Cap$
top bottom
ZEX logo
ZEX
Zeta
6.11M
MDT logo
MDT
Measurable Data Token
5.68M
AKE logo
AKE
AKEDO
9.28M
KIN logo
KIN
Kindred Labs
1.88M
UNITE logo
UNITE
Unite
106.81K
CHILLGUY logo
CHILLGUY
Just a chill guy
11.99M
no which two coins under .01
Intellectia · 347 candidates
Turnover 24h: >= 0Price: $0.00 - $0.01Relative Vol: >= 0Dollar Volume 24h: >= 0
Ticker
Name
Market Cap$
top bottom
PEPE logo
PEPE
Pepe
1.65B
G logo
G
Gravity
56.10M
PUMP logo
PUMP
Pump.fun
716.00M
BONK logo
BONK
Bonk
579.97M
PENGU logo
PENGU
Pudgy Penguins
498.58M
SHIB logo
SHIB
Shiba Inu
3.66B
What stoke should I buy ?
Intellectia · 60 candidates
Market Cap: >= 30.00BQuarter Revenue Yoy Growth: >= 10.0%Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 1,500,000
Ticker
Name
Market Cap$
top bottom
LITE logo
LITE
Lumentum Holdings Inc
42.87B
WDC logo
WDC
Western Digital Corp
96.32B
MU logo
MU
Micron Technology Inc
449.96B
FIX logo
FIX
Comfort Systems USA Inc
47.19B
AU logo
AU
Anglogold Ashanti PLC
53.60B
KGC logo
KGC
Kinross Gold Corp
40.90B
stocks to buy tomorrow
Intellectia · 358 candidates
Market Cap: >= 5.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
TER logo
TER
Teradyne Inc
43.25B
DINO logo
DINO
HF Sinclair Corp
10.32B
MT logo
MT
ArcelorMittal SA
44.06B
AROC logo
AROC
Archrock Inc
5.35B
EXAS logo
EXAS
Exact Sciences Corp
19.49B
AEP logo
AEP
American Electric Power Company Inc
64.75B
show me large cap stocks with key reversal
Intellectia · 44 candidates
Market Cap: >= 10.00BNew High Low: 52w_High, 52w_Low, 20_High, 20_LowCandlestick Pattern: UpperShadow, LowerShadow
Ticker
Name
Market Cap$
top bottom
WMT logo
WMT
Walmart Inc
949.57B
CSCO logo
CSCO
Cisco Systems Inc
309.45B
AZN logo
AZN
AstraZeneca PLC
287.64B
MRK logo
MRK
Merck & Co Inc
273.69B
TXN logo
TXN
Texas Instruments Inc
193.96B
MFG logo
MFG
Mizuho Financial Group Inc
106.59B
stocks currently in bullish trend
Intellectia · 39 candidates
Market Cap: >= 10.00BList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Quarter Price Change Pct: >= $50.00Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
MU logo
MU
Micron Technology Inc
439.39B
NEM logo
NEM
Newmont Corporation
140.53B
CVNA logo
CVNA
Carvana Co
104.69B
FCX logo
FCX
Freeport-McMoRan Inc
89.29B
B logo
B
Barrick Mining Corp
86.76B
WDC logo
WDC
Western Digital Corp
86.45B
give me your top pick
Intellectia · 10 candidates
Market Cap: >= 10.00BMarket Cap Category: mega, largeAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Predict Return: >= 15.0%
Ticker
Name
Market Cap$
top bottom
ROST logo
ROST
Ross Stores Inc
60.49B
NI logo
NI
NiSource Inc
20.77B
APG logo
APG
APi Group Corp
18.28B
META logo
META
Meta Platforms Inc
1.63T
EME logo
EME
EMCOR Group Inc
31.47B
PEN logo
PEN
Penumbra Inc
14.07B

Whales Holding TEVA

P
Polar Capital Holdings Plc
Holding
TEVA
+33.30%
3M Return
M
Maplelane Capital, LLC
Holding
TEVA
+24.88%
3M Return
M
More Investment House Ltd.
Holding
TEVA
+24.34%
3M Return
C
Clal Financial Management Ltd
Holding
TEVA
+21.30%
3M Return
H
Harel Insurance Investments & Financial Services Ltd
Holding
TEVA
+14.79%
3M Return
A
Altshuler Shaham Ltd.
Holding
TEVA
+14.33%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Teva Pharmaceutical Industries Limited.. (TEVA) stock price today?

The current price of TEVA is 35.93 USD — it has increased 0.56

What is Teva Pharmaceutical Industries Limited.. (TEVA)'s business?

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

What is the price predicton of TEVA Stock?

Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Teva Pharmaceutical Industries Limited.. (TEVA)'s revenue for the last quarter?

Teva Pharmaceutical Industries Limited.. revenue for the last quarter amounts to 3.97B USD, increased 1.33

What is Teva Pharmaceutical Industries Limited.. (TEVA)'s earnings per share (EPS) for the last quarter?

Teva Pharmaceutical Industries Limited... EPS for the last quarter amounts to 0.31 USD, increased 63.16

How many employees does Teva Pharmaceutical Industries Limited.. (TEVA). have?

Teva Pharmaceutical Industries Limited.. (TEVA) has 31173 emplpoyees as of May 11 2026.

What is Teva Pharmaceutical Industries Limited.. (TEVA) market cap?

Today TEVA has the market capitalization of 41.60B USD.